- Home
- GH vs IESC Comparison
GH vs IESC Comparison
Compare GH & IESC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- IESC
- Stock Information
- Founded
- GH 2011
- IESC 1997
- Country
- GH United States
- IESC United States
- Employees
- GH N/A
- IESC N/A
- Industry
- GH Medical Specialities
- IESC Engineering & Construction
- Sector
- GH Health Care
- IESC Industrials
- Exchange
- GH Nasdaq
- IESC Nasdaq
- Market Cap
- GH 4.9B
- IESC 5.4B
- IPO Year
- GH 2018
- IESC 1998
- Fundamental
- Price
- GH $54.62
- IESC $371.23
- Analyst Decision
- GH Strong Buy
- IESC
- Analyst Count
- GH 17
- IESC 0
- Target Price
- GH $58.24
- IESC N/A
- AVG Volume (30 Days)
- GH 2.4M
- IESC 139.2K
- Earning Date
- GH 11-05-2025
- IESC 08-01-2025
- Dividend Yield
- GH N/A
- IESC N/A
- EPS Growth
- GH N/A
- IESC 53.94
- EPS
- GH N/A
- IESC 13.08
- Revenue
- GH $828,849,000.00
- IESC $3,249,431,000.00
- Revenue This Year
- GH $28.07
- IESC $17.29
- Revenue Next Year
- GH $21.61
- IESC $11.11
- P/E Ratio
- GH N/A
- IESC $28.85
- Revenue Growth
- GH 28.74
- IESC 17.84
- 52 Week Low
- GH $20.14
- IESC $146.52
- 52 Week High
- GH $68.00
- IESC $388.70
- Technical
- Relative Strength Index (RSI)
- GH 41.10
- IESC 57.76
- Support Level
- GH $53.67
- IESC $336.93
- Resistance Level
- GH $61.95
- IESC $388.70
- Average True Range (ATR)
- GH 2.29
- IESC 14.88
- MACD
- GH -1.51
- IESC 1.50
- Stochastic Oscillator
- GH 7.33
- IESC 62.50
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About IESC IES Holdings Inc.
IES Holdings Inc owns and manages subsidiaries that design and installs integrated electrical and technology systems and provide infrastructure products and services. It has four business segments; Communications, Residential, Infrastructure Solutions, and Commercial & Industrial. The majority of the revenue for the company is generated from its Residential segment in which the company provides electrical installation services for single-family housing and multi-family apartment complexes, as well as heating, ventilation, and air conditioning (HVAC) and plumbing installation services. This segment also provides services for installing residential solar power, both for new construction and existing residences.